PSMA PET may lead to misdiagnosis, unnecessary changes in treatment

PET imaging is a common tool to establish the stage of a patient’s prostate cancer, but new research raises questions about its association with misdiagnosis and unnecessary changes in therapies. Benign tissues in the kidney, bowels and salivary glands may show increased prostate-specific membrane antigen (PSMA) expression, prompting experts to caution against relying solely on PSMA PET.

“It is important that nuclear medicine physicians be aware of this pitfall, as the interpretation of PSMA PET scans may have a substantial impact on therapy guidance,” said Christoph Rischpler, MD, of Germany’s Technical University in Munich. Read more.

Tags: Cancer PET Prostate Research

About NMC  |  Products  |  Quote  |  News  |  Resources  |  Contact  |  Sitemap